ReproCELL

ServiceYokohama, JapanFounded 2003· One of 2247 Service companies tracked by AMPulse

Integrated research and medical company specializing in iPS and ES cell technologies for drug discovery and regenerative medicine.

CEO / Founder: Chikafumi Yokoyama (Global CEO), Rama Modali (CEO, REPROCELL USA)
Team Size: 51-200
Stage: Active
Total Funding: $21.7M
Latest Round: Grant
Key Investors: NorthStar Ventures, Business Investment Group (BiG), Mitsubishi UFJ Capital, SBI Investment, Nissay Capital, DBJ Capital, Maryland Stem Cell Research Fund

Technology & Products

Key Products

iPSC-derived cell products, GMP manufacturing services, StemEdit clinical gene editing services, human tissue research services, stem cell technologies for drug discovery and regenerative medicine, iPSC-derived exosomes.

Technological Advantage

Integrated platform spanning research reagents, drug discovery assays, and MHLW-licensed clinical-grade cell processing (CDMO).

Differentiation

Value Proposition

Accelerates drug discovery and regenerative medicine through high-quality iPSC-derived cell products and integrated GMP manufacturing services, reducing clinical development risks.

How They Differentiate

First-mover advantage in iPSC commercialization and a global footprint established through strategic acquisitions of BioServe, Stemgent, Reinnervate, and Biopta.

Market & Competition

Target Customers

Pharmaceutical companies, academic researchers, medical device manufacturers, and regenerative medicine providers.

Industry Verticals

Pharmaceutical; Medical; Academic Research; Biotechnology

Competitors

Cyfuse Biomedical, Organovo, Cellink

Growth & Milestones

Growth Metrics

Publicly listed on Tokyo Stock Exchange (4978); Capital of ¥2,688M; Global operations in Japan, USA, UK, and India.

Major Milestones

2003: Founded by Profs. Nakatsuji and Nakauchi; 2005: Launched first human ES cell culture medium; 2009: Launched world's first iPSC-derived cardiomyocytes; 2013: Listed on Japan JASDAQ / Growth stock market; 2014: Acquired Reinnervate (Alvetex 3D cell culture); 2022: Completed Phase II clinical trial of Stemchymal; 2026: Opened GMP-compliant cell culture facility at REPROCELL USA (Beltsville, MD)

Notable Customers

Ajinomoto, Steminent Biotherapeutics

https://www.reprocell.com

Official records

Filings, certifications, and programme counts AMPulse can show for this company.

[C] ISO_9001 · claimed

Why this company matters

AMPulse analysis, not a company disclosure

ReproCELL occupies a distinctive position as an integrated provider of stem cell technologies for drug discovery and regenerative medicine, bridging the gap between academic research and clinical-grade manufacturing. Founded in 2003 by Professors Nakatsuji and Nakauchi, the company was an early mover in commercializing induced pluripotent stem cell (iPSC) products, launching the world's first commercial iPSC-derived cardiomyocytes in 2009 and iPSC-derived neurons in 2010. These products were utilized in Nobel Prize-winning iPSC research, establishing the company's credibility in the field.

The company's core offering spans iPSC-derived cell products, GMP manufacturing services, and human tissue research services. Its technological platform integrates research reagents, drug discovery assays, and MHLW-licensed clinical-grade cell processing, functioning as a CDMO for regenerative medicine. Key technologies include proprietary RNA-based iPSC reprogramming, the Alvetex 3D cell culture platform (acquired via Reinnervate), and Stemchymal cell processing technology.

ReproCELL serves pharmaceutical companies, academic researchers, medical device manufacturers, and regenerative medicine providers. Notable customers include Ajinomoto and Steminent Biotherapeutics. The company has established a global footprint through strategic acquisitions of BioServe, Stemgent, Reinnervate, and Biopta, with operations in Japan, the USA, the UK, and India. Key partnerships include PerkinElmer Japan, Takara Bio, and Kyoto University.

The company's competitive moat rests on its first-mover advantage in iPSC commercialization and its integrated platform spanning research to GMP manufacturing. However, competition from firms like Cyfuse Biomedical, Organovo, and Cellink, as well as the broader shift toward automated 3D bioprinting and organ-on-a-chip platforms, presents ongoing risk. ReproCELL is publicly listed on the Tokyo Stock Exchange (4978) and has raised over $21.7 million from investors including NorthStar Ventures and Mitsubishi UFJ Capital.